Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Opening Keynote: The Future of Rare Disease Trials Patient-Centric Commercialization: Integrating Patient Voices into Market Access Strategies Adaptive & Precision-Driven Trials: Platform and MATCH Models for Rare Disease Breakthroughs Case Studies in Rare Disease Commercialization: Lessons Learned Optimizing CRO and Vendor Selection - Examples from the Field
Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Opening Keynote: The Future of Rare Disease Trials Patient-Centric Commercialization: Integrating Patient Voices into Market Access Strategies Adaptive & Precision-Driven Trials: Platform and MATCH Models for Rare Disease Breakthroughs Case Studies in Rare Disease Commercialization: Lessons Learned Optimizing CRO and Vendor Selection - Examples from the Field
